AlphaGrep UK’s Recursion Pharmaceuticals RXRX Stock Holding History

AlphaGrep UK’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-33,063	Closed	-$135K	–	914
2025 Q4	$135K	Buy	+33,063	New	+$164K	0.05%	645

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AlphaGrep UK's RXRX Position: Q1 2026 in Review

AlphaGrep UK sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 33,063 shares — an estimated $135K sold.

AlphaGrep UK first reported a position in RXRX in Q4 2025 and held it in 1 quarter. The position peaked at $135K in Q4 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

AlphaGrep UK reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
AlphaGrep UK sold 33,063 Recursion Pharmaceuticals shares in Q1 2026, an estimated $135K.
AlphaGrep UK first reported a position in Recursion Pharmaceuticals in Q4 2025 and held it in 1 quarter.
AlphaGrep UK's Recursion Pharmaceuticals position peaked at $135K in Q4 2025.
335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on AlphaGrep UK's 13F filing for Q1 2026, filed 13 Aug 2026.